Introduction: The prevalence of patients with ‘borderline’ levels of cardiovascular risk factors has been rarely investigated, being often reported in studies evaluating abnormal values of these parameters. The BORDERLINE study represents a pilot experience to primarily identify the prevalence of ‘high-normal’ conditions, such as pre-hypertension, lipid and glucose levels in the upper range of normality in the setting of general practice in Italy.
Aim: The aim of this study was to evaluate the prevalence of patients with ‘borderline’ values of cardiovascular risk factors in Italy.
Methods: Involved physicians were asked to evaluate the first 20 outpatients, consecutively seen in June 2009. Data were collected in a study-designed case-report form, in which physicians identified thresholds rather than reported absolute values of several clinical parameters. High-normal values were defined as follows: blood pressure (BP) 130–140/85–90 mmHg; total cholesterol 180–200 mg/dL; low-density lipoprotein cholesterol (LDL-C) 130–150 mg/dL; high-density lipoprotein cholesterol (HDL-C) 30–40 mg/dL in males and 40–50 mg/dL in females; triglycerides 130–150 mg/dL and fasting glucose 100–110 mg/dL. Results: Fifty-three Italian physicians provided valuable clinical data on 826 individual outpatients, among which 692 (83.7%, 377 women, mean age 60.9±13.2 years, body mass index 26.6±5.0 kg/m2) were included in the present analysis. Prevalence of borderline values of systolic BP and total cholesterol levels were at least comparable with those in the normal limits of the corresponding parameters, whereas prevalence of borderline diastolic BP, LDL-C, HDL-C, triglycerides and fasting glucose levels was significantly lower than that of normal values, but higher than that of abnormal values of the corresponding parameters.
Conclusions: Using this sample of healthy subjects in the setting of general practice in Italy, our results demonstrated a relatively high prevalence of borderline values of cardiovascular risk factors, which was at least comparable with that of normal, but significantly higher than that of abnormal thresholds. These preliminary findings may prompt more extensive investigations in the area of ‘borderline’ cardiovascular risk. This information may, in fact, potentially enable the design of more effective prevention strategies in the future to limit the burden of cardiovascular disease in the general population in Italy.
Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009 Mar 14; 373(9667): 929–40PubMedCrossRefGoogle Scholar
Volpe M. 2008 White paper for implementing strategies and interventions for cardiovascular prevention in Italy. High Blood Press Cardiovasc Prev 2008; 15(2): 63–73PubMedCrossRefGoogle Scholar
Morrell J, Zeymer U, Baumgartner I, et al. Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe. Eur J Cardiovasc Prev Rehabil 2011 Apr; 18(2): 270–7PubMedCrossRefGoogle Scholar
Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. J Hum Hypertens 2008 Feb; 22(2): 154–7PubMedCrossRefGoogle Scholar
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 Feb 7; 358(6): 580–91PubMedCrossRefGoogle Scholar
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 Jan 30; 348(5): 383–93PubMedCrossRefGoogle Scholar
Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10–16; 366(9489): 895–906PubMedCrossRefGoogle Scholar
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361(9364): 1149–58PubMedCrossRefGoogle Scholar
Manuel DG, Lim J, Tanuseputro P, et al. Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006 Mar 18; 332(7542): 659–62PubMedCrossRefGoogle Scholar
Sasamura H, Nakaya H, Julius S, et al. The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design. Hypertens Res 2008 Oct; 31(10): 1843–9PubMedCrossRefGoogle Scholar
Ren J, Dominguez LJ, Sowers JR, et al. Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes 1999 Oct; 48(10): 2059–65PubMedCrossRefGoogle Scholar
Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991 Feb; 229(2): 181–7PubMedCrossRefGoogle Scholar
Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res 2008 May; 31(5): 921–9PubMedCrossRefGoogle Scholar
Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007; 46(17): 1331–6PubMedCrossRefGoogle Scholar
Bahadir O, Uzunlulu M, Oguz A, et al. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 2007 Jan; 30(1): 49–53PubMedCrossRefGoogle Scholar
Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25(9): 1751–62PubMedCrossRefGoogle Scholar
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004 Aug; 24(8): e149–61PubMedCrossRefGoogle Scholar
Sesti G, Volpe M, Cosentino F, et al. Metabolic syndrome: diagnosis and clinical management: an Official Document of the Working Group of the Italian Society of Cardiovascular Prevention (SIPREC). High Blood Press Cardiovasc Prev 2006; 13(4): 185–98CrossRefGoogle Scholar
Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 Jan; 28(1): 88–136PubMedCrossRefGoogle Scholar
Volpe M, Borghi C, Cavallo Perin P, et al. Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance. High Blood Press Cardiovasc Prev 2010; 17(2): 73–102CrossRefGoogle Scholar
Palmieri L, Panico S, Vanuzzo D, et al. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist Super Sanita 2004; 40(4): 393–9PubMedGoogle Scholar
Volpe M, Tocci G, Trimarco B, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007 Jul; 25(7): 1491–8PubMedCrossRefGoogle Scholar
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics: 2010 update - a report from the American Heart Association. Circulation 2010 Feb 23; 121(7): e46–215PubMedCrossRefGoogle Scholar
Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 Sep; 14Suppl. 2: S1–113PubMedCrossRefGoogle Scholar
Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003 Jul 29; 108(4): 414–9PubMedCrossRefGoogle Scholar
DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998 Aug 8; 317 (7155): 371–5Google Scholar
Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007 Dec; 78(3): 305–12PubMedCrossRefGoogle Scholar